The complete directory of therapies your VidaVital provider may discuss with you. Every entry includes bloodwork status, regulatory status, and a consultation link.
A provider-directed GLP-1 receptor agonist that may support medical weight management, appetite regulation, and blood sugar control.
A provider-directed dual GLP-1 and GIP receptor agonist that may support medical weight management and blood sugar control.
A compounded, investigational peptide fragment of human growth hormone being evaluated for body composition support alongside medical weight management.
A growth-hormone-releasing hormone (GHRH) analog. FDA-approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; any other use is off-label.
A compounded growth-hormone-releasing hormone (GHRH) analog that some providers use as part of a broader plan supporting the growth-hormone axis in eligible adults.
A compounded combination of a short-acting GHRH analog (CJC-1295 no DAC) and a growth-hormone secretagogue (ipamorelin) that some providers use to support the growth-hormone axis.
A compounded, selective growth-hormone secretagogue that some providers use to support pulsatile growth-hormone release in eligible adults.
An investigational, compounded peptide being evaluated for tissue-support and recovery goals in eligible adults.
An investigational, compounded peptide fragment being evaluated for tissue-support and recovery goals in eligible adults.
A compounded, investigational combination of BPC-157 and TB-500 that some providers use as part of a broader recovery plan.
An investigational, compounded copper-tripeptide being evaluated for skin, hair, and soft-tissue support goals.
A compounded, investigational blend of GHK-Cu, BPC-157, and TB-500 that some providers use as part of a skin and tissue-support plan.
A compounded, investigational blend of KPV, GHK-Cu, BPC-157, and TB-500 that some providers use for skin, tissue, and recovery support.
A compounded, investigational tripeptide being evaluated for anti-inflammatory and immune-support goals.
A compounded cofactor infusion or injection that some providers use as part of a broader plan supporting cellular energy and healthy-aging goals.
A compounded antioxidant that some providers use as part of a broader plan supporting oxidative-stress-related, skin, or wellness goals.
An investigational, compounded mitochondrial-derived peptide being evaluated for cellular energy and healthy-aging goals. Not positioned as a weight-loss therapy at VidaVital.
A melanocortin-receptor agonist. FDA-approved (as Vyleesi) only for acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women. Any other use is off-label.
A compounded, investigational hypothalamic peptide being evaluated for support of the hypothalamic-pituitary-gonadal axis in eligible adults.
A compounded, investigational immunomodulatory peptide that some providers use as part of a broader plan supporting immune resilience in eligible adults.
20 therapies in the Phase 1 catalog.
Not sure where to start? Find My Options →The information provided on this website is for general educational purposes and is not medical advice, a diagnosis, or a prescription. Treatment recommendations are not final until a licensed medical provider completes a live consultation, reviews your medical history and medications, evaluates relevant laboratory results, and determines that treatment is medically appropriate.
Certain treatments may be prepared by a compounding pharmacy pursuant to an individual prescription. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing.
Your results identify subjects to discuss with a provider. They do not establish medical eligibility or guarantee that any medication will be prescribed.
This website is not intended for emergencies. Call 911 or seek immediate medical attention for urgent or severe symptoms.
